Contraline released promising data from the clinical trial it’s conducting to test the efficacy of Adam, its male birth control product. The nonhormonal gel seems to be doing a good job of blocking the flow of sperm to the vas deferens, and no serious adverse events have been reported.
Medical device company Contraline became the first to implant a hydrogel-based male contraceptive gel into humans in a clinical trial. Implanted during a noninvasive 10-minute office procedure, the gel promises to block the flow of sperm to the vas deferens. If proven safe and effective, it could become the first nonhormonal, reversible contraceptive for men on the market.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The subject of IUDs might be controversial to some, but those in the healthcare field are having an open conversation.
Intrauterine devices (IUDs) are a 99 percent effective, insertable form of long-acting contraception (lasts for years), which use copper or hormones to block sperm from fertilizing eggs. They have become an increasingly popular form of contraception, but many pediatricians providing birth control for teens haven’t been trained to insert them. Gynecologists are up-to-date with the […]